. Author manuscript; available in PMC: 2014 Oct 1.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2013 Jul 26;13(5):515–529. doi: 10.1016/j.clml.2013.03.018

Table 5.

National Comprehensive Cancer Network Recommendations for the Selection of Different Treatment Options Based on BCR-ABL Kinase Domain Mutation Status⁵

Mutation	Therapeutic Options
Mutation	Imatinib	High-dose Imatinib	HSCT	Nilotinib	Dasatinib	Ponatinib	Bosutinib	Omacetaxine	Clinical Trial
T315I			✓			✓^a		✓	✓
V299L				✓		✓		✓^b
T315A	✓^c			✓		✓	✓	✓^b
F317L/V/I/C				✓		✓	✓	✓^b
Y253H,E255K/V,F359V/I/C					✓	✓	✓	✓^b
Any other mutation		✓^d		✓	✓	✓	✓	✓^b

Abbreviation: HSCT = hematopoietic stem cell transplantation.

Preferred option.

Omacetaxine is an option for patients with resistance or intolerance to ≥ 2 TKIs.

If mutation detected after dasatinib.

There are not sufficient data on dose escalation available to indicate if mutations with lower IC values are sensitive to high dose imatinib.

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Chronic Myelogenous Leukemia V.4.2013 © National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines^® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK^®, NCCN^®, NCCN GUIDELINES^®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.